EMA Authorised: Opdualag (nivolumab;relatlimab) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Opdualag, a fixed-dose combination of nivolumab and relatlimab, for melanoma, with Bristol-Myers Squibb Pharma EEIG as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 12/02/2026